CellWell record HH-19218
Bioequivalence of mulberry fruit extract and 1-deoxynojirimycin for post-prandial blood glucose lowering: A randomized trial in humans
Hoogenraad AR et al.
The Journal of Nutrition ยท 2025
In plain language
A randomized bioequivalence trial found the postprandial glucose-lowering effect of mulberry extract is largely attributable to its 1-deoxynojirimycin content, with other extract components contributing modestly. This is the key citation for why standardizing to DNJ is the meaningful specification.
- Evidence
- Established
- Design
- Randomized controlled trial
- Studied in
- Human
Cite this record: https://thecellwell.org/studies/HH-19218
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.